

REMARKS

The specification has been amended to correct errors in Example 2 and clarify that clotrimazole is the active and caprylyl pyrrolidone is the solvent in the formulation of Example 2. Clotrimazole is a preferred active (see e.g. page 5), and caprylyl pyrrolidone is a common solvent to the formulations of Examples 1-9. No new matter has been added.


Attached hereto is a marked-up version of the changes made to the specification by the current amendment. The attached page is captioned "Version with markings to show changes made".

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to Deposit Account No. 03-1952 referencing docket no. 468452000200.

Respectfully submitted,

Dated: August 7, 2002

By:


Cameron A. King
Registration No. 41,897

Morrison & Foerster LLP
425 Market Street
San Francisco, California 94105-2482
Telephone: (415) 268-6524
Facsimile: (415) 268-7522

VERSION WITH MARKINGS TO SHOW CHANGES MADEIn the Specification:

The table on page 7, titled "Example 1" has been amended as follows:

Ingredient	Class	% W/W
<u>Clotrimazole</u> [Caprylyl pyrrolidone]	Pharmaceutical active	2
<u>Caprylyl pyrrolidone</u> [Surfadone LP 100]	Solvent	10
PEG 400	Organic bulking agent	60.5
Hydroxypropycellulose	Thickening agent	4
Cocamidopropyl Betaine	Surfactant/booster	2.5
Sodium Cocoamphacetate	Mild surfactant	4
Sodium Lauryl Ether Sulfate	Detergent	7
Ammonium Lauryl Sulfate	Detergent	10